Physician profile
Maher N Nashed
NPI 1649264425
$1,098.97
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $171 · 2021: $74.81 · 2022: $268 · 2023: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $383.33 | 2019-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $187.90 | 2019-2023 | Symbicort |
| Novartis Pharmaceuticals Corporation | $99.56 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $94.87 | 2019-2023 | Dupixent |
| Biocryst US Sales Co., LLC | $71.02 | 2022-2023 | Orladeyo |
| Genzyme Corporation | $63.53 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.65 | 2020-2023 | Takhzyro |
| Pfizer INC. | $29.77 | 2019 | |
| Bio Products Laboratory USA, INC. | $29.33 | 2021-2022 | |
| Amgen INC. | $24.40 | 2023 | Tezspire |
| Otsuka America Pharmaceutical, INC. | $19.44 | 2022 | |
| Lundbeck LLC | $18.31 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Nashed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.